United Therapeutics (UTHR) Tops Q2 EPS by 18c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $503.86 -0.58%
Revenue Growth %: -1.2%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $7.27, $0.18 better than the analyst estimate of $7.09. Revenue for the quarter came in at $783.3 million versus the consensus estimate of $807.05 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microsoft plans data center push to triple its computing power - Bloomberg
- B.Riley Starts Neuronetics (STIM) at Buy
- UBS Upgrades SD Guthrie (SDG:MK) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
